Phase III trial of Sci-B-Vac

Trial Profile

Phase III trial of Sci-B-Vac

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 19 Jun 2017 According to a VBI Vaccines media release, the company plans to submit the IND in the second half of 2017, along with the Clinical Trial Applications (CTAs) for Europe and Canada. Additional details will be available at the time the IND and CTA submissions.
    • 22 Feb 2017 According to a VBI Vaccines media release, the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada has expressed it's general support to the Phase III clinical program of Sci-B-Vac.
    • 10 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top